instanyl
takeda pharma a/s - fentanyl citrate - pain; cancer - analgetika - instanyl er indiceret til behandling af gennembrudssmerter hos voksne, der allerede modtager opioidbehandling ved vedligeholdelse af kronisk kræftpine. gennembrudssmerter er en forbigående forværring af smerte, der opstår på baggrund af ellers kontrolleret vedvarende smerte. patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.
palexia 50 mg filmovertrukne tabletter
grünenthal gmbh - tapentadolhydrochlorid - filmovertrukne tabletter - 50 mg
palexia depot 100 mg depottabletter
grünenthal gmbh - tapentadolhydrochlorid - depottabletter - 100 mg
palexia depot 150 mg depottabletter
grünenthal gmbh - tapentadolhydrochlorid - depottabletter - 150 mg
palexia depot 200 mg depottabletter
grünenthal gmbh - tapentadolhydrochlorid - depottabletter - 200 mg
palexia depot 250 mg depottabletter
grünenthal gmbh - tapentadolhydrochlorid - depottabletter - 250 mg
palexia depot 50 mg depottabletter
grünenthal gmbh - tapentadolhydrochlorid - depottabletter - 50 mg
palexia retard 100 mg depottabletter
paranova danmark a/s - tapentadolhydrochlorid - depottabletter - 100 mg
palexia retard 150 mg depottabletter
paranova danmark a/s - tapentadolhydrochlorid - depottabletter - 150 mg
palexia depot 150 mg depottabletter
2care4 aps - tapentadolhydrochlorid - depottabletter - 150 mg